Robust IPO activity in late 2026 reflects favorable equity market conditions, with 267 U.S. deals completed year-to-date through mid-November and multiple offerings priced in recent weeks, including vVARDIS Holding and Windward Bio Group. Primary drivers include strong investor demand for AI and biotech names, supportive valuations, and a pipeline of large filings such as Anthropic’s S-1, which set terms for a potential November 19 pricing targeting tens of billions in proceeds. Recent data show continued filings and roadshows through December, alongside SPAC activity, indicating sustained issuance momentum before year-end. Key upcoming catalysts include additional pricing windows in the final six weeks of 2026 and any shifts in Treasury yields or equity volatility that could affect underwriting calendars.